IMPROVING THE EFFICACY AND SAFETY OF ADOPTIVE CELLULAR THERAPIES
The disclosure relates generally to the generation and use of immune effector cells (e.g., T cells, NK cells) engineered to express an immune receptor (e.g., Chimeric Antigen Receptor, Synthetic Immune Receptor, T Cell Receptor etc.) to treat a disease associated with expression of a target antigen.
1 . A method of manufacturing an immune effector cell therapy product comprising treating a donor subject with:
(a) a CXCR4 antagonist;
(b) a cytokine;
(c) a chemotherapeutic agent;
(d) a beta2 adrenergic agonist;
(e) a Src kinase inhibitor;
(f) exercise so as to reach a heart rate at least >25% higher than the heart rate at rest; or
(g) a combination of one or more of (a), (b), (c), (d), (e) or (f);
isolating blood from the donor subject;
isolating an immune effector cell or population thereof from the blood; and
optionally transforming the immune effector cell or population thereof with a heterologous polynucleotide to express or over express an endogenous or exogenous immune receptor, a chimeric antigen receptor (CAR) or a T cell receptor, wherein the immune receptor, CAR or T cell receptor comprises at least one antigen-binding domains and at least one transmembrane domain; or
optionally expanding the immune effector cell or population thereof in culture for a period of 1 to 30 days.
2 . The method of claim 1 , wherein the immune effector cell or population thereof has reduced, eliminated or altered expression and/or function of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1/BLIMP1 HDAC2, JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11, BRAF, CD27, CD28, 41BB, DcR1, DcR2, OX40, GITR, BCMA, TRAIL, DR4 and/or DR5.
3 . The method of claim 1 , wherein the antigen-binding domain binds to a tumor antigen selected from a group consisting of: CD5, CD19; CD123; CD22; CD30; CD171; CS-1 (also referred to as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant Ill (EGFRviii); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(I-4)bDGlcp(I-I)Cer); TNF receptor family member B cell maturation (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser/Thr)); prostate-specific membrane antigen (PSMA); Receptor tyrosine kinase-like orphan receptor 1 (ROR1); FmsLike Tyrosine Kinase 3 (FLT3); Tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; a glycosylated CD43 epitope expressed on acute leukemia or lymphoma but not on hematopoietic progenitors; a glycosylated CD43 epitope expressed on non-hematopoietic cancers; Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); Interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); Mesothelin; Interleukin 11 receptor alpha (IL-IIRa); prostate stem cell antigen (PSCA); Protease Serine 21 (Testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet-derived growth factor receptor beta (PDGFR-beta); Stage-specific embryonic antigen-4 (SSEA-4); CD20/MS4A1; Folate receptor alpha; Receptor tyrosine-protein kinase ERBB2 (Her2/neu); Mucin 1, cell surface associated (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); Prostase; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); Ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); glycoprotein 100 (gp100); oncogene fusion protein consisting of breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl) (bcr-abl); tyrosinase; ephrin type-A receptor 2 (EphA2); Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDClalp(I-4)bDGlcp(I-1)Cer); transglutaminase 5 (TGS5); high molecular weight-melanomaassociated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Polysialic acid; placenta-specific 1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51 E2 (OR51 E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); Cancer/testis antigen 1 (NY-ESO-1); Cancer/testis antigen 2 (LAGE-1a); Melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member IA (XAGEI); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; survivin; telomerase; prostate carcinoma tumor antigen-1 (PCT A-1 or Galectin 8); melanoma antigen recognized by T cells 1 (MelanA or MARTI); Rat sarcoma (Ras) mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-Acetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin BI; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Tyrosinase-related protein 2 (TRP-2); Cytochrome P450 IB 1 (CYPIB 1); CCCTC-Binding Factor (Zinc Finger Protein)-Like (BORIS or Brother of the Regulator of Imprinted Sites), Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TESI); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); Receptor for Advanced Glycation End products (RAGE-1); renal ubiquitous 1 (RUI); renal ubiquitous 2 (RU2); legumain; human papilloma virus E6 (HPV E6); human papilloma virus E7 (HPV E7); intestinal carboxyl esterase; heat shock protein 70-2 mutated (mut hsp70-2); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIRI); Fc fragment of IgA receptor (FCAR or CD89); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family memberf (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); immunoglobulin lambda-like polypeptide 1 (IGLLI), MPL; Biotin; c-MYC epitope Tag; CD34; LAMP1 TROP2; GFRalpha4; CDH17; CDH6; NYBR1; CDH19; CD200R; Slea (CA19.9; Sialyl Lewis Antigen) Fucosyl-GM1; PTK7; gpNMB; CDH1-CD324; DLL3; CD276/B7H3; IL11Ra; IL13Ra2; CD179b-IGLI1; ALK TCRgamma-delta; NKG2D; CD32 (FCGR2A); CSPG4-HMW-MAA; Tim1-/HVCR1; CSF2RA (GM-CSFR-alpha); TGFbetaR2; VEGFR2/KDR; Lews Ag; TCR-beta1 chain; TCR-beta2 chain; TCR-gamma chain; TCR-delta chain; FITC; Leutenizing hormone receptor (LHR); Follicle stimulating hormone receptor (FSHR); Chorionic Gonadotropin Hormone receptor (CGHR); CCR4; SLAMF6; SLAMF4; HIV1 envelope glycoprotein; HTLV1-Tax; CMV pp65; EBV-EBNA3c; influenza A hemagglutinin (HA); GAD; PDL1; Guanylyl cyclase C (GCC); KSHV-K8.1 protein; KSHV-gH protein; auto-antibody to desmoglein 3 (Dsg3); autoantibody to desmoglein 1 (Dsg1); HLA; HLA-A; HLA-A2; HLA-B; HLA-C; HLA-DP; HLA-DM; HLA-DOA; HLA-DOB; HLA-DQ; HLA-DR; HLA-G; IGE; CD99; RAS G12V; Tissue Factor 1 (TF1); AFP; GPRC5D; claudin18.2 (CLD18A2 OR CLDN18A.2)); P-glycoprotein; STEAP1; LIV1; NECTIN-4; CRIPTO; MPL; GPA33; BST1/CD157; low conductance chloride channel; Integrin B7; Muc17; C16ORF54; VISTA; Muc5Ac; FCRH5; CLDN6; MMP16, UPK1B; BMPR1 B; Ly6E, WISP1 and SLC34A2.
4 - 9 . (canceled)
10 . The method of claim 1 , wherein the immune effector cell or population thereof is engineered to express a constitutive active mutant of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and/or BRAF.
11 . The method of claim 1 , wherein the expression and/or function of BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes (e.g., Tet1, Tet2, Tet3), ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1/BLIMP1, HDAC2, TRAIL, and/or DR5, is reduced or eliminated and expression and function of JAK1, JAK3, STAT5b, STAT3, IL2RG, CARD11 and/or BRAF is enhanced in the immune effector cell or population thereof.
12 . The method of claim 1 , wherein the immune effector cell or population thereof expresses a CAR, a next generation CAR or a TCR.
13 - 15 . (canceled)
16 . The method of claim 1 , wherein the CXCR4 antagonist is selected from the group consisting of Plerixafor or BL-80400.
17 - 28 . (canceled)
29 . A method of manufacturing an immune effector cell therapy product of claim 11 , the method comprising introducing polynucleotide encoding a CAR/TCR into an immune effector cell such that said polynucleotide integrates into the genome of the immune effector cell within a BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes, ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1/BLIMP1, HDAC2, TRAIL, and/or DR5 gene or intron or exon thereof of wherein expression and/or function is reduced or eliminated.
30 . A method of manufacturing an immune effector cell therapy product of claim 11 , the method comprising contacting said immune effector cell ex vivo with a BRD9, EZH2, MLL2, MLL3, MLL4, methylcytosine dioxygenase genes, ATM, CHEK, FBXW10, BCOR, FAT1, ASXL1, PHF6, SF3B1, YY1, CBFb, Runx1, EHMT2 (G9A), SMARCA4, CREBBP, PRDM1/BLIMP1, HDAC2, TRAIL, and/or DR5 inhibitor.
31 - 51 . (canceled)
52 . A method of manufacturing an immune effector cell therapy product of claim 1 comprising exposing the cell to a bispecific or multispecific engager in the presence of an antigen presenting cell or an anti-presenting substrate.
53 . The method of claim 52 , where the bispecific or multi-specific engager comprises at least one antigen binding domain capable of engaging the immune effector cell and at least one antigen binding domain capable of engaging an antigen presenting cell (APC) or antigen presenting substrate (APS).
54 . The method of claim 53 , where the APC is a hematopoietic cell, a B cell lineage cell or wherein the cell comprises a CD19 antigen.
55 - 56 . (canceled)
57 . The method of claim 53 , where the APC is selected from the group consisting of a REC-1, JEKO-1, MINO, GRANTA-519, NALM6 and RAJI cell.
58 - 59 . (canceled)
60 . A method of claim 52 , where the method further involves exposing the immune effector cells to an agonist that activates a costimulatory receptor on immune cells
61 . The method of claim 52 , wherein the bispecific or multispecific engager comprises at least one binding domain capable of binding to and activating the T cell receptor (TCR) complex of T cells.
62 . (canceled)
63 . The method of claim 52 , wherein the bispecific or multispecific engager comprises at least one binding domain capable of binding to and activating a receptor on the T cells that provides co-stimulation.
64 . The method of claim 63 , where the receptor bound by the bispecific or multispecific engager is selected from the group consisting of CD28, CD137 (4-1BB), CD134 (OX40), Dap10, CD27, CD2, CD5, ICAM-1, LFA-1, TNFR-I, TNFR-II, Fas, CD30 and CD40.
65 - 83 . (canceled)
84 . A method of expanding and/or activating an immune effector cell comprising administering to a subject a bispecific or multispecific T cell engager.
85 . A method of claim 84 , where the bispecific or multi-specific engager contains at least one antigen binding domain capable of engaging the immune cells and at least one antigen binding domain capable of engaging an antigen presenting cell (APC).
86 . The method of claim 85 , wherein the APC is a hematopoietic cell, a B cell lineage cell or a cell expressing the CD19 antigen.
87 - 153 . (canceled)